Osteoporosis

被引：1058

作者：

Sambrook, Philip ^{[1
]}

Cooper, Cyrus

机构：

[1] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2065, Australia

[2] Univ Southampton, MRC, Epidemiol Resource Ctr, Southampton, Hants, England

来源：

LANCET | 2006年 / 367卷 / 9527期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1016/S0140-6736(06)68891-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteoporosis is a serious public health issue. The past 10 years have seen great advances in our understanding of its epidemiology, pathophysiology, and treatment, and further advances are rapidly being made. Clinical assessment win probably evolve from decisions mainly being made on the basis of bone densitometry, to use of algorithms of absolute fracture risk. Biochemical markers of bone turnover are also likely to become more widely used. Bisphosphonates will probably remain the mainstay of therapy, but improved understanding of the optimum amount of remodelling suppression and duration of therapy will be important. At the same time, other diagnostic and therapeutic approaches, including biological agents, are likely to become more widespread.

引用

页码：2010 / 2018

页数：9

共 98 条

[1] Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].

Anderson, GL ;

Limacher, M ;

Assaf, AR ;

Bassford, T ;

Beresford, SAA ;

Black, H ;

Bonds, D ;

Brunner, R ;

Brzyski, R ;

Caan, B ;

Chlebowski, R ;

Curb, D ;

Gass, M ;

Hays, J ;

Heiss, G ;

Hendrix, S ;

Howard, BV ;

Hsia, J ;

Hubbell, A ;

Jackson, R ;

Johnson, KC ;

Judd, H ;

Kotchen, JM ;

Kuller, L ;

LaCroix, AZ ;

Lane, D ;

Langer, RD ;

Lasser, N ;

Lewis, CE ;

Manson, J ;

Margolis, K ;

Ockene, J ;

O'Sullivan, MJ ;

Phillips, L ;

Prentice, RL ;

Ritenbaugh, C ;

Robbins, J ;

Rossouw, JE ;

Sarto, G ;

Stefanick, ML ;

Van Horn, L ;

Wactawski-Wende, J ;

Wallace, R ;

Wassertheil-Smoller, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712

[2]

[Anonymous], 2001, Osteoporosis, DOI [10.1016/B978-012470862-4/50022-2, DOI 10.1016/B978-012470862-4/50022-2]

[3] Fracture prevention with vitamin D supplementation - A meta-analysis of randomized controlled trials [J].

Bischoff-Ferrari, HA ;

Willett, WC ;

Wong, JB ;

Giovannucci, E ;

Dietrich, T ;

Dawson-Hughes, B .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (18) :2257-2264

[4] One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].

Black, DM ;

Bilezikian, JP ;

Ensrud, KE ;

Greenspan, SL ;

Palermo, L ;

Hue, T ;

Lang, TF ;

McGowan, JA ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565

[5] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[6] LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women [J].

Bollerslev, J ;

Wilson, SG ;

Dick, IM ;

Islam, FMA ;

Ueland, T ;

Palmer, L ;

Devine, A ;

Prince, RL .

BONE, 2005, 36 (04) :599-606

[7] Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].

Bone, HG ;

Hosking, D ;

Devogelaer, J ;

Tucci, JR ;

Emkey, RD ;

Tonino, RP ;

Rodriguez-Portales, JA ;

Downs, RW ;

Gupta, J ;

Santora, AC ;

Liberman, UA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199

[8] Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study [J].

Bonjour, JP ;

Chevalley, T ;

Ammann, P ;

Slosman, D ;

Rizzoli, R .

LANCET, 2001, 358 (9289) :1208-1212

[9] The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts [J].

Bord, S ;

Ireland, DC ;

Beavan, SR ;

Compston, JE .

BONE, 2003, 32 (02) :136-141

[10] High bone density due to a mutation in LDL-receptor-related protein 5 [J].

Boyden, LM ;

Mao, JH ;

Belsky, J ;

Mitzner, L ;

Farhi, A ;

Mitnick, MA ;

Wu, DQ ;

Insogna, K ;

Lifton, RP .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (20) :1513-1521

← 1 2 3 4 5 6 7 8 9 10 →